CCNE1 AMPLIFICATION
Clinical trials for CCNE1 AMPLIFICATION explained in plain language.
Never miss a new study
Get alerted when new CCNE1 AMPLIFICATION trials appear
Sign up with your email to follow new studies for CCNE1 AMPLIFICATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…
Matched conditions: CCNE1 AMPLIFICATION
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill INX-315 takes on advanced breast and ovarian cancers
Disease control Recruiting nowThis study tests a new oral drug called INX-315 in 150 people with advanced breast cancer, ovarian cancer, or other solid tumors that have not responded to standard treatments. The drug is given alone or combined with other cancer drugs (fulvestrant or abemaciclib). The goal is t…
Matched conditions: CCNE1 AMPLIFICATION
Phase: PHASE1, PHASE2 • Sponsor: Incyclix Bio • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study is the first to test AVZO-021, an oral drug that blocks a protein called CDK2, in people with advanced solid tumors. The trial will enroll about 430 adults with certain breast, ovarian, or other cancers. The goal is to find safe doses and see if the drug can shrink tum…
Matched conditions: CCNE1 AMPLIFICATION
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC